300 related articles for article (PubMed ID: 17707805)
1. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
3. Preparation and biological evaluation of [(99m)Tc/EDDA/Tricine/HYNIC(0), BzThi(3)]-octreotide for somatostatin receptor-positive tumor imaging.
Erfani M; Shafiei M; Mazidi M; Goudarzi M
Cancer Biother Radiopharm; 2013 Apr; 28(3):240-7. PubMed ID: 23464855
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy.
De K; Bhowmik A; Behera A; Banerjee I; Ghosh MK; Misra M
J Pept Sci; 2012 Dec; 18(12):720-30. PubMed ID: 23109400
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of (99m)Tc-HYNIC-His(3)-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors.
Behera A; Banerjee I; De K; Munda RN; Chattopadhayay S; Samanta A; Sarkar B; Ganguly S; Misra M
Amino Acids; 2013 Mar; 44(3):933-46. PubMed ID: 23090293
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
[TBL] [Abstract][Full Text] [Related]
7. Tetraamine-modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice.
Nikolopoulou A; Maina T; Sotiriou P; Cordopatis P; Nock BA
J Pept Sci; 2006 Feb; 12(2):124-31. PubMed ID: 16059963
[TBL] [Abstract][Full Text] [Related]
8. (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors.
Dong C; Zhao H; Yang S; Shi J; Huang J; Cui L; Zhong L; Jin X; Li F; Liu Z; Jia B; Wang F
Mol Pharm; 2013 Aug; 10(8):2925-33. PubMed ID: 23768172
[TBL] [Abstract][Full Text] [Related]
9. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
10. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
11. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
Maina T; Nock BA; Cordopatis P; Bernard BF; Breeman WA; van Gameren A; van den Berg R; Reubi JC; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):831-40. PubMed ID: 16568203
[TBL] [Abstract][Full Text] [Related]
12. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence.
Decristoforo C; Mather SJ
Eur J Nucl Med; 1999 Aug; 26(8):869-76. PubMed ID: 10436200
[TBL] [Abstract][Full Text] [Related]
13. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
14. Radiopharmaceutical development of a freeze-dried kit formulation for the preparation of [99mTc-EDDA-HYNIC-D-Phe1, Tyr3]-octreotide, a somatostatin analog for tumor diagnosis.
Guggenberg EV; Mikolajczak R; Janota B; Riccabona G; Decristoforo C
J Pharm Sci; 2004 Oct; 93(10):2497-506. PubMed ID: 15349959
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours.
von Guggenberg E; Dietrich H; Skvortsova I; Gabriel M; Virgolini IJ; Decristoforo C
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1209-18. PubMed ID: 17308920
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Ginj M; Chen J; Walter MA; Eltschinger V; Reubi JC; Maecke HR
Clin Cancer Res; 2005 Feb; 11(3):1136-45. PubMed ID: 15709181
[TBL] [Abstract][Full Text] [Related]
17. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c(RGDfK)]2 for breast cancer imaging.
Ortiz-Arzate Z; Santos-Cuevas CL; Ocampo-García BE; Ferro-Flores G; García-Becerra R; Estrada G; Gómez-Argumosa E; Izquierdo-Sánchez V
Nucl Med Commun; 2014 Apr; 35(4):423-32. PubMed ID: 24335877
[TBL] [Abstract][Full Text] [Related]
18. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
19. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides.
Vallabhajosula S; Moyer BR; Lister-James J; McBride BJ; Lipszyc H; Lee H; Bastidas D; Dean RT
J Nucl Med; 1996 Jun; 37(6):1016-22. PubMed ID: 8683294
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical evaluation of a new indirectly labeled ⁹⁹mTc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-depreotide with HYNIC as bifunctional chelator.
Yu F; Lü ML; Zhang XP; Fu D; Hou M; Cai HD; Li D; Wang J; Yuan XY; Lü ZW; Dong F
Chin Med J (Engl); 2012 Jul; 125(14):2538-42. PubMed ID: 22882936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
